Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
2.950
-0.270 (-8.39%)
Aug 14, 2025, 11:50 AM - Market open
Immuneering Employees
Immuneering had 66 employees as of December 31, 2024. The number of employees decreased by 2 or -2.94% compared to the previous year.
Employees
66
Change (1Y)
-2
Growth (1Y)
-2.94%
Revenue / Employee
n/a
Profits / Employee
-$941,346
Market Cap
107.14M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66 | -2 | -2.94% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Dec 31, 2020 | 26 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMRX News
- 20 hours ago - Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - Immuneering Granted U.S. Composition of Matter Patent for Highly Differentiated Cancer Drug Candidate Atebimetinib - GlobeNewsWire
- 2 months ago - Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients - GlobeNewsWire
- 2 months ago - Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewsWire
- 2 months ago - Immuneering to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 5 months ago - Immuneering Corporation Announces Grant of Inducement Award - GlobeNewsWire